There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll ...

Shares of Equifax Inc. EFX slid 1.28% to $274.78 Friday, on what proved to be an all-around grim trading session for the ...

Akero Therapeutics Inc . (NASDAQ: AKRO )的首席开发官Yale Catriona最近进行了一系列涉及公司普通股的股票交易。2025年1月27日，Catriona出售的股票总价值约为301万美元。售价范围在每股55.156美元至57.024美元之间，接近公司52周高点58.40美元。该股表现出色，过去一年回报率超过156%，目前市值为38.6亿美元。根据 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Equifax (EFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...

Inspire Investing LLC boosted its position in shares of Equifax Inc. (NYSE:EFX – Free Report) by 4.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Morgan Stanley lowered the firm’s price target on Equifax (EFX) to $316 from $320 and keeps an Overweight rating on the shares. While the firm ...

US clinical-stage liver disease focused biotech Akero Therapeutics saw its shares almost double to $51.71 yesterday, after it ...